| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
|
Hepatology
|
2013
|
5.03
|
|
2
|
Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells.
|
Cell Stem Cell
|
2009
|
4.52
|
|
3
|
Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells.
|
Cell Stem Cell
|
2010
|
4.21
|
|
4
|
Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells.
|
Nat Cell Biol
|
2010
|
3.51
|
|
5
|
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
|
Hepatology
|
2010
|
3.00
|
|
6
|
Nature and duration of growth factor signaling through receptor tyrosine kinases regulates HSV-1 latency in neurons.
|
Cell Host Microbe
|
2010
|
2.65
|
|
7
|
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
|
Hepatology
|
2013
|
2.36
|
|
8
|
Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
|
J Hepatol
|
2006
|
2.09
|
|
9
|
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
|
Gut
|
2010
|
1.85
|
|
10
|
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
|
J Hepatol
|
2008
|
1.76
|
|
11
|
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.
|
Intervirology
|
2005
|
1.71
|
|
12
|
Generation of a functional and durable vascular niche by the adenoviral E4ORF1 gene.
|
Proc Natl Acad Sci U S A
|
2008
|
1.69
|
|
13
|
Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
|
J Hepatol
|
2012
|
1.53
|
|
14
|
Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
|
J Gastroenterol
|
2003
|
1.45
|
|
15
|
Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan.
|
J Gastroenterol
|
2004
|
1.42
|
|
16
|
Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
|
J Gastroenterol
|
2004
|
1.41
|
|
17
|
Performance of extracorporeally adjustable ventricular assist device inflow cannula.
|
Ann Thorac Surg
|
2010
|
1.39
|
|
18
|
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
|
J Clin Virol
|
2012
|
1.35
|
|
19
|
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.
|
J Infect Dis
|
2011
|
1.33
|
|
20
|
Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice.
|
J Biol Chem
|
2002
|
1.29
|
|
21
|
Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.
|
Hepatology
|
2007
|
1.16
|
|
22
|
Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
|
Hepatology
|
2011
|
1.12
|
|
23
|
Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
|
J Med Virol
|
2007
|
1.10
|
|
24
|
The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.
|
J Hepatol
|
2003
|
1.05
|
|
25
|
Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
|
J Med Virol
|
2006
|
1.04
|
|
26
|
Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.
|
J Med Virol
|
2009
|
1.01
|
|
27
|
Axial and centrifugal continuous-flow rotary pumps: a translation from pump mechanics to clinical practice.
|
J Heart Lung Transplant
|
2013
|
1.01
|
|
28
|
Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.
|
J Gastroenterol
|
2013
|
1.00
|
|
29
|
Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.
|
Intervirology
|
2007
|
0.99
|
|
30
|
Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
|
J Clin Virol
|
2009
|
0.99
|
|
31
|
Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.
|
J Med Virol
|
2007
|
0.98
|
|
32
|
Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan.
|
J Med Virol
|
2005
|
0.98
|
|
33
|
A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
|
J Med Virol
|
2009
|
0.97
|
|
34
|
YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
|
J Med Virol
|
2004
|
0.97
|
|
35
|
Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
|
Intervirology
|
2009
|
0.96
|
|
36
|
Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.
|
J Gastroenterol
|
2004
|
0.95
|
|
37
|
Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
|
J Med Virol
|
2012
|
0.94
|
|
38
|
Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
|
Intervirology
|
2007
|
0.94
|
|
39
|
Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1.
|
J Med Virol
|
2013
|
0.94
|
|
40
|
Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C.
|
J Viral Hepat
|
2012
|
0.94
|
|
41
|
Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.
|
Hepatology
|
2012
|
0.92
|
|
42
|
Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes.
|
J Virol Methods
|
2006
|
0.92
|
|
43
|
Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up.
|
J Med Virol
|
2005
|
0.91
|
|
44
|
Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.
|
Am J Med
|
2006
|
0.91
|
|
45
|
Effect of implant support on distal-extension removable partial dentures: in vivo assessment.
|
Int J Oral Maxillofac Implants
|
2009
|
0.91
|
|
46
|
Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.
|
J Clin Microbiol
|
2013
|
0.91
|
|
47
|
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy.
|
Intervirology
|
2009
|
0.90
|
|
48
|
Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection.
|
J Gastroenterol
|
2004
|
0.90
|
|
49
|
Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.
|
J Med Virol
|
2010
|
0.90
|
|
50
|
Versatile roles of R-Ras GAP in neurite formation of PC12 cells and embryonic vascular development.
|
J Biol Chem
|
2006
|
0.90
|
|
51
|
Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
|
J Med Virol
|
2009
|
0.89
|
|
52
|
Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
|
J Med Virol
|
2011
|
0.89
|
|
53
|
Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy.
|
J Med Virol
|
2003
|
0.89
|
|
54
|
Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.
|
J Clin Virol
|
2007
|
0.88
|
|
55
|
Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival.
|
Scand J Gastroenterol
|
2005
|
0.88
|
|
56
|
Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.
|
Intervirology
|
2012
|
0.88
|
|
57
|
Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan.
|
J Gastroenterol
|
2012
|
0.87
|
|
58
|
Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.
|
Intervirology
|
2003
|
0.87
|
|
59
|
[Psychiatric background of social withdrawal in adolescence].
|
Seishin Shinkeigaku Zasshi
|
2007
|
0.87
|
|
60
|
Accuracy of oral mucosal thickness measurements using spiral computed tomography.
|
J Periodontol
|
2010
|
0.87
|
|
61
|
Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice.
|
Neuroreport
|
2002
|
0.87
|
|
62
|
Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.
|
Hepatol Res
|
2009
|
0.86
|
|
63
|
Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay.
|
J Virol Methods
|
2010
|
0.86
|
|
64
|
Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.
|
Hepatol Res
|
2011
|
0.86
|
|
65
|
Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.
|
Intervirology
|
2011
|
0.86
|
|
66
|
Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
|
J Med Virol
|
2007
|
0.86
|
|
67
|
Augmented delayed infarct expansion and reactive astrocytosis after permanent focal ischemia in apolipoprotein E4 knock-in mice.
|
J Cereb Blood Flow Metab
|
2004
|
0.86
|
|
68
|
Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection.
|
J Gastroenterol
|
2012
|
0.86
|
|
69
|
Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.
|
J Gastroenterol
|
2012
|
0.86
|
|
70
|
Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.
|
J Med Virol
|
2011
|
0.85
|
|
71
|
Mechanical circulatory support for heart failure: past, present and a look at the future.
|
Expert Rev Med Devices
|
2013
|
0.85
|
|
72
|
Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.
|
J Med Virol
|
2014
|
0.85
|
|
73
|
Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.
|
Intervirology
|
2012
|
0.85
|
|
74
|
Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance.
|
Liver Int
|
2006
|
0.85
|
|
75
|
HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
|
Liver Int
|
2010
|
0.85
|
|
76
|
Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients.
|
Hepatol Res
|
2012
|
0.84
|
|
77
|
Novel action of apolipoprotein E (ApoE): ApoE isoform specifically inhibits lipid-particle-mediated cholesterol release from neurons.
|
Mol Neurodegener
|
2007
|
0.84
|
|
78
|
Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.
|
J Med Virol
|
2008
|
0.84
|
|
79
|
Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.
|
Hepatol Res
|
2011
|
0.84
|
|
80
|
Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.
|
Intervirology
|
2004
|
0.83
|
|
81
|
Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
|
J Gastroenterol Hepatol
|
2009
|
0.83
|
|
82
|
A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
|
J Med Virol
|
2013
|
0.83
|
|
83
|
Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load.
|
Hepatol Res
|
2003
|
0.83
|
|
84
|
Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL.
|
Hepatol Res
|
2012
|
0.82
|
|
85
|
[Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer].
|
Gan To Kagaku Ryoho
|
2010
|
0.82
|
|
86
|
Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay.
|
J Virol Methods
|
2012
|
0.82
|
|
87
|
Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.
|
J Gastroenterol Hepatol
|
2010
|
0.82
|
|
88
|
Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy.
|
Hepatol Res
|
2007
|
0.82
|
|
89
|
Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis.
|
J Gastroenterol
|
2004
|
0.81
|
|
90
|
Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy.
|
Hepatol Res
|
2011
|
0.81
|
|
91
|
Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.
|
Intern Med
|
2007
|
0.81
|
|
92
|
Increased vulnerability to focal ischemic brain injury in human apolipoprotein E4 knock-in mice.
|
J Neuropathol Exp Neurol
|
2003
|
0.81
|
|
93
|
Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
|
J Med Virol
|
2004
|
0.81
|
|
94
|
Clinical and virological effects of long-term (over 5 years) lamivudine therapy.
|
J Med Virol
|
2010
|
0.81
|
|
95
|
A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.
|
Intern Med
|
2003
|
0.81
|
|
96
|
Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance.
|
Intervirology
|
2007
|
0.80
|
|
97
|
Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.
|
J Med Virol
|
2012
|
0.80
|
|
98
|
Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load.
|
Intervirology
|
2004
|
0.80
|
|
99
|
Effects of implant surgery on blood pressure and heart rate during sedation with propofol and midazolam.
|
Int J Oral Maxillofac Implants
|
2012
|
0.80
|
|
100
|
Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.
|
J Clin Microbiol
|
2013
|
0.80
|
|
101
|
Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
|
J Med Virol
|
2006
|
0.80
|
|
102
|
Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.
|
Hepatol Res
|
2013
|
0.80
|
|
103
|
Accelerated Abeta aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain.
|
FEBS Lett
|
2004
|
0.80
|
|
104
|
Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load.
|
Hepatol Res
|
2012
|
0.80
|
|
105
|
Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C.
|
J Med Virol
|
2013
|
0.80
|
|
106
|
Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
|
Oncology
|
2016
|
0.79
|
|
107
|
In vivo evaluation of the "TinyPump" as a pediatric left ventricular assist device.
|
Artif Organs
|
2011
|
0.79
|
|
108
|
Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C.
|
Intervirology
|
2005
|
0.79
|
|
109
|
Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.
|
Hepatol Res
|
2011
|
0.79
|
|
110
|
The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.
|
Intern Med
|
2011
|
0.79
|
|
111
|
Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.
|
Intervirology
|
2010
|
0.79
|
|
112
|
Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis.
|
J Gastroenterol
|
2004
|
0.79
|
|
113
|
Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment.
|
Intervirology
|
2005
|
0.79
|
|
114
|
[A retrospective analysis of cetuximab or panitumumab monotherapy for KRAS wild-type metastatic colorectal cancer in clinical practice].
|
Gan To Kagaku Ryoho
|
2015
|
0.78
|
|
115
|
Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C.
|
J Med Virol
|
2009
|
0.78
|
|
116
|
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.
|
Intern Med
|
2010
|
0.78
|
|
117
|
HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy.
|
Liver Int
|
2014
|
0.78
|
|
118
|
Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C.
|
Intervirology
|
2008
|
0.78
|
|
119
|
Protective effects of cold spinoplegia with fasudil against ischemic spinal cord injury in rabbits.
|
J Vasc Surg
|
2010
|
0.78
|
|
120
|
Implant overdenture using Konus telescope on one-piece implant: a case report.
|
Eur J Prosthodont Restor Dent
|
2009
|
0.78
|
|
121
|
Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C.
|
Intern Med
|
2008
|
0.78
|
|
122
|
Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis.
|
J Med Virol
|
2013
|
0.78
|
|
123
|
Efficacy of interferon therapy in elderly patients with chronic hepatitis C.
|
Intervirology
|
2006
|
0.78
|
|
124
|
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.
|
Intern Med
|
2011
|
0.78
|
|
125
|
A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b.
|
J Virol Methods
|
2006
|
0.78
|
|
126
|
Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
|
J Med Virol
|
2008
|
0.78
|
|
127
|
The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load.
|
Intern Med
|
2008
|
0.78
|
|
128
|
The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2.
|
Intern Med
|
2009
|
0.77
|
|
129
|
Functional mitral regurgitation: modern concepts for ventricular geometry reshaping.
|
Expert Rev Med Devices
|
2012
|
0.77
|
|
130
|
Developmental capacity of Antarctic minke whale ( Balaenoptera bonaerensis ) vitrified oocytes following in vitro maturation, and parthenogenetic activation or intracytoplasmic sperm injection.
|
Zygote
|
2006
|
0.77
|
|
131
|
Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment.
|
Intervirology
|
2009
|
0.77
|
|
132
|
Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
|
J Med Virol
|
2005
|
0.77
|
|
133
|
Randomized, controlled trial of natural interferon-alpha therapy for e-antigen-positive chronic hepatitis B patients.
|
Hepatol Res
|
2002
|
0.77
|
|
134
|
Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
|
J Gastroenterol
|
2004
|
0.77
|
|
135
|
Prolonged hepatitis after acute infection with genotype H hepatitis B virus.
|
Intern Med
|
2007
|
0.77
|
|
136
|
Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load.
|
Hepatol Res
|
2012
|
0.77
|
|
137
|
Hemodynamic differences between the awake and anesthetized conditions in normal calves.
|
J Artif Organs
|
2012
|
0.77
|
|
138
|
Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.
|
Intern Med
|
2009
|
0.76
|
|
139
|
The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load.
|
Intern Med
|
2008
|
0.76
|
|
140
|
Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis.
|
Dig Dis Sci
|
2010
|
0.76
|
|
141
|
Usefulness of the serum KL-6 assay in patients with hepatitis C virus.
|
Intervirology
|
2005
|
0.76
|
|
142
|
Effect of acute self-limited hepatitis C virus (HCV) superinfection on hepatitis B virus (HBV)-related cirrhosis. Virological features of HBV-HCV dual infection.
|
Dig Dis Sci
|
2004
|
0.76
|
|
143
|
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.
|
Intern Med
|
2010
|
0.76
|
|
144
|
Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.
|
J Gastroenterol
|
2013
|
0.76
|
|
145
|
Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load.
|
Intern Med
|
2008
|
0.76
|
|
146
|
Effects of human apolipoprotein E isoforms on the amyloid beta-protein concentration and lipid composition in brain low-density membrane domains.
|
J Neurochem
|
2007
|
0.76
|
|
147
|
Development of a disposable maglev centrifugal blood pump intended for one-month support in bridge-to-bridge applications: in vitro and initial in vivo evaluation.
|
Artif Organs
|
2009
|
0.76
|
|
148
|
Glucose depletion enhances sensitivity to shear stress-induced mechanical damage in red blood cells by rotary blood pumps.
|
Artif Organs
|
2009
|
0.75
|
|
149
|
In vivo evaluation of a new surfactant polymer coating mimicking the glycocalyx of endothelial cells.
|
ASAIO J
|
2011
|
0.75
|
|
150
|
Characterization of antifungal activity of the GH-46 subclass III chitosanase from Bacillus circulans MH-K1.
|
Antonie Van Leeuwenhoek
|
2013
|
0.75
|
|
151
|
Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
|
Intervirology
|
2012
|
0.75
|
|
152
|
Reply: To PMID 22991257.
|
Hepatology
|
2013
|
0.75
|
|
153
|
Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin.
|
Intern Med
|
2007
|
0.75
|
|
154
|
A network system of medical and welfare information service for the patients, their families, hospitals, local governments, and commercial companies in a medical service area.
|
J Med Syst
|
2002
|
0.75
|
|
155
|
Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
|
J Med Virol
|
2007
|
0.75
|
|
156
|
Long-term clinical evaluation of implant over denture.
|
J Prosthodont Res
|
2011
|
0.75
|
|
157
|
HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B.
|
J Med Virol
|
2003
|
0.75
|
|
158
|
Early in vivo evaluation of ventricular assistance with a miniature centrifugal blood pump (TinyPump) in rabbits.
|
ASAIO J
|
2010
|
0.75
|
|
159
|
Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b.
|
J Med Virol
|
2015
|
0.75
|
|
160
|
ANNALS EXPRESS: Performance of autotaxin as a serum marker of liver fibrosis.
|
Ann Clin Biochem
|
2017
|
0.75
|
|
161
|
N-Hexyl-4-aminobutyl glycosides for investigating structures and biological functions of carbohydrates.
|
Org Biomol Chem
|
2009
|
0.75
|
|
162
|
Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.
|
J Med Virol
|
2012
|
0.75
|
|
163
|
Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
|
Oncology
|
2017
|
0.75
|
|
164
|
Changes in viral loads of lamivudine-resistant mutants during entecavir therapy.
|
Hepatol Res
|
2007
|
0.75
|
|
165
|
Serial measurements of accommodation by open-field Hartmann-Shack wavefront aberrometer in eyes with accommodative spasm.
|
Jpn J Ophthalmol
|
2012
|
0.75
|
|
166
|
Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
|
J Med Virol
|
2005
|
0.75
|
|
167
|
In vitro culture conditions using chemically defined media for in vitro matured and intracytoplasmically inseminated porcine oocytes.
|
J Reprod Dev
|
2006
|
0.75
|
|
168
|
The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load.
|
Intervirology
|
2008
|
0.75
|
|
169
|
Arterial switch operation using aortic homograft for transposition of the great arteries with pulmonary regurgitation.
|
Jpn J Thorac Cardiovasc Surg
|
2006
|
0.75
|